Labopharm is notified of Actavis' filing for a generic Oleptro

11/14/2010 | Reuters

Actavis has notified Labopharm of its FDA filing for a generic version of Oleptro, the latter's once-daily treatment for depression. Labopharm, which is reviewing the formal notice, has market exclusivity for the drug through Feb. 2, 2013.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA